CN113876736A - Near-infrared response bionic nano preparation and preparation method and application thereof - Google Patents
Near-infrared response bionic nano preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN113876736A CN113876736A CN202111160742.7A CN202111160742A CN113876736A CN 113876736 A CN113876736 A CN 113876736A CN 202111160742 A CN202111160742 A CN 202111160742A CN 113876736 A CN113876736 A CN 113876736A
- Authority
- CN
- China
- Prior art keywords
- cas9
- ucnps
- nano
- avidin
- crispr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
The invention provides a near-infrared response bionic nano preparation. The bionic nano preparation comprises a cell membrane of an HBV hepatocyte model and a nano carrier wrapped in the cell membrane, wherein the nano carrier comprises near-infrared response up-conversion nanoparticles and CRISPR/Cas9, avidin proteins are modified on the surfaces of the up-conversion nanoparticles, and biotin-modified photolysis molecules are connected between the avidin proteins and CRISPR/Cas 9. The method solves the problems that a CRISPR/Cas9 delivery system in the prior art is high in immunogenicity, low in targeting property, small in carrying load and incapable of realizing remote space-time operation. Establishes a high-efficiency CRISPR/Cas9 delivery system with low immunogenicity, high targeting property, large carrying load and simple and convenient production and synthesis, and implements accurate remote space-time operation on CRISPR/Cas 9.
Description
Technical Field
The invention relates to the technical field of DNA recombination, in particular to a near-infrared response bionic nano preparation and a preparation method and application thereof.
Background
Hepatitis B Virus (HBV) infection is one of the major public health problems facing the world. There are currently about 3 hundred million HBV infected people worldwide, with nearly 1 hundred million in china, reported by WHO; nearly 100 million deaths occur each year from HBV infection, half of which are in china. The current clinical drugs for treating hepatitis B patients mainly comprise two categories of interferon and nucleoside (acid) analogues, aiming at reducing HBV DNA in serum and liver tissues of patients. However, in the long course of treatment, patients have drug-resistant mutations and risks of transformation to liver fibrosis, cirrhosis and carcinoma, and although the drugs can significantly inhibit HBV replication, none of them can directly act on HBV replication template, covalently closed circular DNA (cccDNA), in the hepatocyte nucleus, and thus cannot completely eliminate the covalently closed circular DNA in vivo, resulting in difficulty in completely curing hepatitis b. HBV cccDNA is the source of HBV chronic infection and relapse, and the expression level of the HBV cccDNA is an important index for clinically monitoring the curative effect of antiviral treatment and guiding a treatment scheme.
Currently, research on HBV cccDNA target therapy is mainly performed from two aspects, namely, inhibition of HBV cccDNA formation, such as negative regulation of cccDNA using target viral proteins HBx and HBc to inhibit its formation. However, this approach may target host proteins, resulting in more toxic side effects. Another aspect is to eliminate HBV cccDNA, epigenetic modification of HBV cccDNA in the hepatocyte nucleus or targeted elimination by gene editing, such as histone modification and DNA methylation modification of targeted HBV cccDNA, etc. and gene editing techniques. However, no effective method for completely eliminating cccDNA in the liver cell nucleus of hepatitis b patients has been found so far, and complete elimination of HBV cccDNA is the key point for complete cure of hepatitis b.
The CRISPR/Cas (clustered regularly interspersed short palindromic repeats/CRISPR-associated proteins) system is an immune system which is currently found in most bacteria and all archaea, and is now a research hotspot in the field of life sciences today. Research shows that the CRISPR/Cas9 system can effectively destroy HBV expression templates and has no obvious cytotoxicity. It could be a potential method to eradicate persistent HBV cccDNA in chronic HBV infected patients.
However, the CRISPR/Cas9 system has a problem to enter cells to play a role, namely how to efficiently deliver two macromolecules simultaneously: cas9 (about 160kDa) and single guide RNA (sgRNA, over 100 base pairs). The current vectors for delivering CRISPR/Cas9 are mainly divided into two major classes, viral vectors and non-viral vectors. Viral vectors (e.g., lentiviruses, adenoviruses, etc.) are commonly used by researchers as a means of delivery to introduce exogenous materials into cells depending on the nature of the delivery. The method is convenient, quick and easy to implement, but the method is very easy to cause canceration, insertion mutation or host immune response in organisms, and brings difficulties for subsequent research and treatment. In recent years, researchers have searched for non-viral vector delivery methods, and a non-viral vector delivery system having no endogenous virus recombination, low immunogenicity, large carrying load, small adverse reaction, and simple production and synthesis is expected to be developed. To date, safe delivery of CRISPR/Cas9 has been preliminarily achieved in vitro and in vivo experiments with non-viral vectors including gold nanoparticles, graphene oxide, polymer nanoparticles, and other nanomaterials. However, a high-efficiency CRISPR/Cas9 delivery system with low immunogenicity, high targeting, large carrying load and simple and convenient production and synthesis is not established at present, and the accurate remote space-time operation on the CRISPR/Cas9 is a main problem faced by researchers.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a near-infrared response bionic nano-carrier and a preparation method and application thereof, and solves the problems that a CRISPR/Cas9 delivery system in the prior art is high in immunogenicity, low in targeting property, small in carrying load and incapable of realizing remote space-time operation.
The invention provides a near-infrared response bionic nano preparation, which comprises a cell membrane of a hepatocyte model and a nano carrier wrapped in the cell membrane, wherein the nano carrier comprises near-infrared response up-conversion nanoparticles and CRISPR/Cas9, the surfaces of the up-conversion nanoparticles are modified with avidin, and a biotin-modified photolysis molecule is connected between the avidin and CRISPR/Cas 9.
A Biotin-modified photolytic molecule (PCB) is a uv-irradiated photocleavable linker comprising Biotin, pc (Photo-cleavable) and a photoresponsive group; the surface of the Upconversion nanoparticles (UCNPs) is modified with Avidin to form Avidin modified Upconversion nanoparticles (UCNPs-Avidin); due to the strong affinity between Avidin and biotin, PCBs can be easily bound to UCNPs-Avidin to form nanoparticle UNCPs-Avidin/PCBs, which are then bound to CRISPR/Cas9 to generate UCNPs-Cas 9; finally, UCNPs-Cas9 is wrapped by the cell membrane of the liver cell model to form the nano preparation. Upon irradiation by Near Infrared (NIR) light, UCNPs convert high-energy NIR light to low-energy UV light, which cleaves PC bonds, thereby releasing CRISPR/Cas9 for controlled gene editing.
Preferably, the hepatocyte model is one of HBV replication hepatocyte model, HBV infected hepatocyte model, primary hepatocyte model.
Preferably, the near-infrared response upconversion nanoparticles are of a core-shell structure, Ca2+Doped NaYF4:Yb3+/Tm3+As a nucleus, NaYF4Yb/Nd is the shell.
Preferably, the biotin-modified photolytic molecule is the PC biotin-nhs ester.
The PC Biotin-NHS Ester (PC Biotin-NHS Ester) comprises an o-nitrophenyl and an N-hydroxysuccinimide (NHS) group which are in photoresponse, the NHS group is connected with an amino group of a Cas9 protein in CRISPR/Cas9, and under the regulation of certain light, the o-nitrophenyl is broken, so that the CRISPR/Cas9 is released.
Preferably, the CRISPR/Cas9 includes a Cas9 protein and sgrnas, the corresponding DNA sequences of which are shown in SEQ ID nos. 1 to 3.
In another aspect of the present invention, a method for preparing a near-infrared response biomimetic nano-formulation is provided, comprising the steps of:
1) construction of CRISPR/Cas 9: designing and synthesizing sgRNA, and co-incubating the sgRNA and Cas9 protein to prepare CRISPR/Cas 9;
2) preparing a nano-carrier UCNPs-Cas 9: synthesizing up-conversion nanoparticles, carrying out hydrophilic modification and Avidin surface modification on the up-conversion nanoparticles to obtain UNCPs-Avidin, then carrying out a connection reaction with a biotin-modified photolysis molecule to form nanoparticle UNCPs-Avidin/PCB, and co-incubating the nanoparticle UNCPs-Avidin/PCB with the CRISPR/Cas9 prepared in the step 1) to obtain a nano-carrier UCNPs-Cas 9;
3) preparing a bionic nano preparation UCNPs-Cas9@ CM: extracting HBV cell membranes of a liver cancer cell replication model, mixing the cell membranes with UCNPs-Cas9 prepared in the step 2), and repeatedly extruding through a polycarbonate filter membrane to obtain UCNPs-Cas9@ CM.
Preferably, in step 1), the molar mass ratio of sgRNA to Cas9 protein is 1:1 to 10:1, the co-incubation time is 5 to 15min, and the temperature is 37 ℃.
Preferably, in step 2), the surface of the up-conversion nanoparticle comprises an oleic acid ligand, the modifier used in the hydrophilic modification is polyacrylic acid, and the method for surface modification of avidin comprises: linking avidin on the surface of the upconversion nanoparticle by using EDC/NHS; the temperature of the connection reaction is 37 ℃ and the time is 2 h; the mass ratio of Avidin to biotin-modified photolytic molecules in UNCPs-Avidin is 1: 4; the temperature of the co-incubation is 4 ℃ and the time is 8-12 h.
Preferably, in step 3), the pore size of the polycarbonate filter membrane is 200nm or 400 nm.
In another aspect, the invention provides an application of a near-infrared response bionic nano preparation in preparing a medicament for treating hepatitis.
The technical principle of the invention is as follows:
UCNPs do not have tissue targeting ability, thereby reducing their therapeutic effect at the site of action. In the prior art, chitosan, PEG and other groups are modified on the surface of UCNPs, and targeting ligands (including antibodies, peptides or aptamers and the like) are added to enhance the targeting property of the UCNPs and prolong the circulation time of the UCNPs in blood. However, this chemical modification is readily recognized by the human immune system and eliminated by the mononuclear phagocyte system. And because the targeting mechanisms of different tissues or cells are greatly different, the application of the artificial micro-nano transport carrier in the field of biomedicine is severely limited. Through repeated experiments, the inventor unexpectedly discovers that the bionic nano preparation obtained by wrapping a cell membrane bionic shell of a hepatocyte model outside UCNPs has better stability, longer blood circulation time and better homotypic fine targeting capability. Meanwhile, Avidin (Avidin) is modified on the surface of UCNPs, the Avidin is combined with biotin in the PCB, and the PCB is connected with CRISPR/Cas9 to form UCNPs-Cas 9; and wrapping the cells by using cell membranes of a hepatocyte model to obtain UCNPs-Cas9@ CM. The UCNPs-Cas9@ CM is accurately delivered to the liver cells by the homologous targeting of the cell membrane of the liver cell model, and the UCNPs-Cas9 enters the liver cells after the UCNPs-Cas9 are internalized by the cells. Under NIR irradiation, UCNPs convert the UCNPs into UV emitted light, and because the PCB comprises a photoresponse group, the absorption spectrum of the photoresponse group is superposed with the emission spectrum of the UCNPs, so that the photoresponse group is broken, CRISPR/Cas9 is released, CRISPR/Cas9 enters cell nucleus under the guidance of a nuclear localization signal, the gene editing function aiming at HBV is exerted, the aim of cooperatively treating the anti-HBV by cell membrane and CRISPR/Cas9 is fulfilled, and the remote space-time operation of the bionic nano preparation is realized.
Compared with the prior art, the invention has the following beneficial effects:
(1) the bionic nano preparation not only has the physical and chemical properties of a nano carrier, but also has the biological activity function similar to that of a target cell without additionally modifying a natural cell membrane of the nano preparation, and has longer blood circulation time and better isomorphism fine targeting capability under physiological conditions; experiments show that the hydrodynamic diameter change of the bionic nano preparation is almost constant within 7 days, and the bionic nano preparation has high stability; the bionic nano preparation (UCNPs-Cas9@ CM2.2.15) coated by the HepG2.2.15 cell membrane is preferentially accumulated in HepG2.2.15 cells, and is obviously superior to the accumulation in 293T (human embryonic kidney cells), HeLa (human cervical cancer cells) and other heterotypic cells, which indicates that the bionic nano preparation has high homotypic cell targeting capability; the bionic nano preparation can escape from the uptake of macrophages, which shows that the nano preparation has the anti-phagocytosis capacity, long blood circulation time and low immunogenicity; and the drug is released under the irradiation of laser to achieve the purpose of synergistic treatment. In the prior art, the up-conversion nanoparticles coated by Polyethyleneimine (PEI) and silicon and PEG do not have targeting property, and have lower anti-phagocytosis performance and stability, so that the treatment effect is poorer;
(2) UCNPs adopt a core-shell structure, and Ca is doped in the core2+Compared with UCNPs without other ion doping, the fluorescence intensity of the UCNPs can be improved; the emission spectrum of the UCNPs is overlapped with the absorption spectrum of the photosensitive molecules at 360nm, so that the UCNPs transfer energy to the photosensitive molecules well through fluorescence resonance energy transfer, the release efficiency of CRISPR/Cas9 is improved, remote control is realized, and the treatment effect is improved;
(3) the surface of UCNPs is modified with avidin, avidin and raw materialThe biotin has high affinity, so that more biotin-modified photosensitive molecules can be connected, more Cas9/sgRNA is loaded, a cascade amplification effect is realized, and a treatment effect is enhanced; in the prior art, upconversion nanoparticles (such as NaYF) are adopted4Yb/Tm) and photosensitive molecules (such as 4-hydroxymethyl-3-nitrobenzoic acid), the amount of Cas9/sgRNA loaded on the carrier is significantly reduced, resulting in limited therapeutic effect;
(4) the off-target effect of the bionic nano preparation can be almost ignored, so that the fixed-point editing efficiency of the bionic nano preparation is improved, the targeting efficiency and the knockout efficiency are improved, and the off-target rate is reduced; the influence on the functional area where the target point is removed is reduced, so that the influence on the expression of other genes is avoided, and the safety of the bionic nano preparation is improved;
(5) the UCNPs are subjected to hydrophilic-hydrophobic assembly, and hydrophilic modification is carried out to remove surface hydrophobic ligands and endow the UCNPs with water solubility, so that the UCNPs can be stably dispersed in water, and have good biocompatibility;
(6) the UCNPs have small particle size, the average diameter is 64nm, and the smaller the particle size, the less the UCNPs are easily phagocytosed as foreign matters by macrophages, so that the treatment effect is improved;
in conclusion, the invention is based on the near-infrared light-controlled triggering CRISPR/Cas9 of biomembrane mediation for the first time to remove HBV cccDNA in a targeted way, has good antiviral effect, can fundamentally remove hepatitis B virus, enables a hepatitis B patient to be cured, provides a new treatment strategy for curing hepatitis B, has low immunogenicity, high targeting property, large carrying load and simple and convenient production and synthesis, can realize the remote operation of accurate time and space of CRISPR/Cas9, improves the treatment effect and efficiency, and is expected to be developed into a novel method for treating hepatitis B with simplicity, reliability and strong practicability.
Drawings
Fig. 1 is an agarose gel electrophoresis of Cas9/sgRNA in vitro sgRNA targeting gene sequences in example 2 of the present invention;
FIG. 2 is a diagram of the characteristic analysis of UCNPs in example 2 of the present invention, wherein A is NaYF4: SEM image of Yb/Tm/Ca; b is a size histogram thereof; c is NaYF4:Yb/Tm/Ca@NaYF4SEM images of Yb/Nd (UCNPs); d is a size histogram of the D; e is an HRTEM image of UCNPs; f is SAED of UCNPs;
FIG. 3 is a diagram of the characteristic analysis of UCNPs in example 2 of the present invention, wherein A is NaYF4: TEM image of Yb/Tm/Ca; b is NaYF4:Yb/Tm/Ca@NaYF4TEM images of Yb/Nd (UCNPs); c is XRD pattern of UCNPs: d is UCNPs and an EDX element analysis chart thereof; e is the ultraviolet-visible absorption spectrum of UCNPs, UCNPs-PAA, Avidin and UCNPs-Avidin in arbitrary units; f is the Fourier infrared spectrum of UCNPs, UCNPs-PAA and UCNPs-Avidin; g is fluorescence spectrum of UCNPs and UCNPs-PAA activated by 808nm laser and ultraviolet absorption spectrum of PC Biotin-NHSester (PCB), and the insets are bright field (left) of UCNPs and fluorescence picture (right) under NIR excitation;
FIG. 4 is a representation of cell membranes in example 3 of the present invention: a is a transmission electron microscope image of CMs, B is the hydrodynamic diameter of CMs, and C is the zeta potential of CMs;
FIG. 5 is a representation of NIR-controlled UCNPs-Cas9@ CM: a is a TEM image of UCNPs-Cas9@ CM; b is an SEM image of UCNPs-Cas9@ CM; c is the hydrodynamic size distribution of CMs, UCNPs and UCNPs-Cas9@ CM; d is zeta potential of Cas9/sgRNA, UCNPs-PAA, UCNPs-Avidin/PCB, UCNPs-Cas9 and UCNPs-Cas9@ CM; e is the SDS-PAGE protein analysis of total cell protein, UCNPs-Cas9@ CM, Avidin and Cas9 protein (36pmol) (from left to right, samples stained with Coomassie brilliant blue; F is the WB analysis of (I) cell lysates and (II) CMs; G is the hydrodynamic diameter of UCNPs-Cas9@ CM as a function of time; H is the determination of the UV absorbance of the supernatant of UCNPs-Cas9 with 808nm laser at different illumination times; I is the CLSM image of cells incubated with UCNPs-Cas9@ CM at NIR/+ illumination (white: GFP-labeled Cas 9; light grey: DAPI);
FIG. 6 is a graph showing the effect of NIR on CRISPR/Cas9 controlled release after UCNPs-Cas9@ CM is internalized by cells by CLSM: a is a graph of the effect of cells incubated with UCNPs-Cas9@ CM in the absence of NIR radiation; b is a graph of the effect of cells incubated with UCNPs-Cas9@ CM under NIR irradiation;
FIG. 7 is a graph showing the results of the immunoescape and isotype targeting experiments for UCNPs-Cas9@ CM: a is a CLSM image and a flow cytometer map of RAW264.7 cells after being co-cultured with UCNPs-Cas9 or UCNPs-Cas9@ CM for 6 hours; b is HepG2.2.15, 293T, Hela, L929 cell and UCNPs-Cas9@ CM2.2.15CLSM images and flow cytometer profiles after 6 hours of co-culture;
FIG. 8 is a CLSM image of Raw264.7 cells after 3 hours or 6 hours of co-culture of Raw264.7 cells with UCNPs-Cas9 and UCNPs-Cas9@ CM;
FIG. 9 is a CLSM image of four cell lines after 1h, 3h or 6h co-culture with UCNPs-Cas9@ CM;
FIG. 10 is a graph of cell viability test results: a is cell viability after irradiation with different NIR powers (fixed 20min, no UCNPs-Cas9@ CM); b is a fixed NIR power of 2.0W/cm2Cell viability at different irradiation times (no UCNPs-Cas9@ CM); c is cell viability after different concentrations of UCNPs-Cas9@ CM (no NIR) treatment; d is UCNPs-Cas9@ CM at different concentrations (NIR power: 2.0W/CM)2Fixation for 20min) cell viability after irradiation; wherein, the UCNPs-Cas9@ CM concentration is marked in the form of Cas9 concentration (uM);
FIG. 11 is a graph of the temperature change of a UCNPs-Cas9@ CM solution with or without NIR radiation;
FIG. 12 shows the gene editing effect of UCNPs-Cas9@ CM on HBV in vitro: a is the experimental result of T7EI in HepG2.2.15 and HepAD38 cells of UCNPs-Cas9@ CM after/without NIR irradiation treatment; B. c is a sequencing result graph of a fragment of the sgRNA17 action targeting gene amplified by PCR in HepG2.2.15 cells; D-F is qRT-PCR analysis UCNPs-Cas9@ CM after NIR irradiation treatment, HBV3.5kb mRNA, intracellular HBV DNA and HBV cccDNA levels in HepG2.2.15 and HepAD38 cells, and PBS treatment group as a negative control; G-H is the ELISA result of HBsAg and HBeAg levels in the supernatant of HepG2.2.15 and HepAD38 cells after the UCNPs-Cas9@ CM is treated by NIR irradiation;
FIG. 13 is a graph showing the results of in vivo biocompatibility and toxicity analysis of UCNPs-Cas9@ CM: a is the hemolytic effect of different concentrations of UCNPs-Cas9@ CM on mouse erythrocytes, and the concentration of UCNPs-Cas9@ CM is marked in the form of Cas9 concentration (uM); b is the blood of the mice treated with UCNPs-Cas9@ CM and PBS respectively after 14 daysFluid normal and blood biochemical levels; c is the change in body weight of mice treated with UCNPs-Cas9@ CM and PBS for 14 days, respectively; d is lanthanide ion in feces and urine within 7 days after intravenous UCNPs-Cas9@ CM (Y)3+) Content (c); e is H of the major organs of the mice after 14 days of treatment with UCNPs-Cas9@ CM and PBS, respectively&E staining, scale bar: 60 um;
FIG. 14 shows the in vivo gene editing effect of UCNPs-Cas9@ CM on HBV: a is the HBV DNA load of serum in the serum of an HBV-Tg mouse detected by adopting qRT-PCR; B-C is the level of HBsAg and HBeAg in the serum of the mouse measured by a chemiluminescence immunoassay method; d is a representative image of HBsAg and HBeAg expression levels in the liver of HBV-Tg mice after 14 days of treatment with UCNPs-Cas9@ CM (immunohistochemical staining, measuring bar: 30 um);
FIG. 15 shows the off-target effect of UCNPs-Cas9@ CM on HepG2.2.15 cells in vitro (A-B) and mouse liver in vivo (C-D): 15A, 15B are light grey to show the list of off-target sequences with mismatched sites and mismatched bases.
Detailed Description
The technical solution of the present invention is further illustrated by the following examples.
Example 1 design to synthesize sgRNA against targeted HBV genome
From the published literature, 3 HBV-specific sgrnas (RT, 6 and 17) were selected, and the sgrnas were transcribed ex vivo from the DNA template using T7RNA polymerase. sgRNA was synthesized using hisscribe t7 rapid high yield RNA synthesis kit (NEB, # E2040S), and then template DNA was removed using dnase i (Takara, #2270A) at 37 ℃ for 15 min. Finally, the resulting RNA was purified using the HiPureRNA kit (magenta, # R2144). The sgrnas obtained were measured using a Nano-500 spectrophotometer (osho) and stored at-80 ℃ until further use. The DNA sequences corresponding to sgRNA RT, sgRNA 6 and sgRNA17 are shown in SEQ ID NO. 1-3. The in vitro transcribed DNA template sequences are shown in Table 1, SEQ ID NO. 4-6.
TABLE 1 DNA template sequences
Note: the underlined part is the target gene sequence, the 5 'end is the T7 promoter, and the 3' end is sgRNA Scaffold.
Example 2 construction and characterization of Cas9/sgRNA System
1. The synthesized sgRNA was incubated with Cas9 protein (EGFP-Cas9-NLS, available from Nanjing King sry science and technology) with Nuclear Localization Signal (NLS) and GFP expression at 37 ℃ for 10min in a molar mass ratio of 1:1 to form a complex Cas 9/sgRNA.
Activity detection of in vitro cutting HBV cccDNA by Cas9/sgRNA
2.1 PCR amplifying target segment containing sgRNA target gene sequence by using PCH9/3091 plasmid as template. The sequences of the primers used are shown in Table 2, SEQ ID NO. 7-12.
TABLE 2 primer sequences
2.2 sgRNA, Cas9 and 10 × reaction buffer (200mM HEPES, 1M NaCl, 50mM MgCl)21mM EDTA, pH6.5) the reaction system was prepared as shown in Table 3. Then 5ul of the purified full-length PCR Fragment (FL) with the sgRNA target sequence was added and reacted at 37 ℃ for 2 h. And finally detecting the enzyme digestion efficiency by using 1% agarose gel electrophoresis.
TABLE 3 reaction System for in vitro cleavage of HBV cccDNA by Cas9/sgRNA
The results of the experiment are shown in FIG. 1. The results show that: cas9/sgRNA17 has higher cleavage efficiency.
Example 3 preparation and characterization of nanocarrier UCNPs-Cas9
1. Preparation of calcium oleate precursor
6.09g of sodium oleate (NaOA) was dissolved in 20mL of absolute ethanol and mixed with 10mL of a calcium nitrate solution (10mM) in a round-bottom flask. Then, 35ml of cyclohexane was added, and the mixed solution was heated under reflux at 80 ℃ for 4 hours. After completion, the mixture was cooled to room temperature and transferred to a separatory funnel. The upper layer was collected and washed with water. And finally, removing residual cyclohexane through rotary evaporation to obtain a white calcium oleate precursor.
2.Ca2+Doped NaYF4:Yb3+/Tm3+(NaYF4Yb/Tm/Ca) synthesis
0.5mM of naked nucleus precursor LnCl3The aqueous solution was added to a three-necked flask and heated to 100 ℃ until solid chloride, LnCl, was formed3The aqueous solution comprised 0.1205g of yttrium chloride (YCl)3·6H2O), 0.03874g of ytterbium chloride (YbCl)3·6H2O) and 0.000958g of thulium chloride (TmCl)3·6H2O). Then, 30mg of calcium oleate precursor, 3.75mL of Oleic Acid (OA), and 7.5mL of Octadecene (ODE) were added to give mixture 1. Mixture 1 was heated to 150 ℃ and stirred for 1.5h to form a homogeneous solution, which was then cooled to room temperature. Then, 0.05g of NaOH and ammonium fluoride (NH) were added4F) 5mL of 0.074g methanol solution was added dropwise to the reaction, stirred at 50 ℃ for 30min, the solution was heated to 100 ℃ for 30min, and methanol was evaporated. The solution was then heated at 300 ℃ for 1.5h and then cooled to room temperature. All experiments were performed under argon. Finally, 2 times the volume of absolute ethanol is added for precipitation, the mixture is centrifuged at 12000rpm for 5min, washed several times with ethanol/cyclohexane (1:1v/v), 4mL of cyclohexane is dispersed to obtain Ca2+Doped NaYF4:Yb3+/Tm3+And (3) solution.
3.NaYF4:Yb/Tm/Ca@NaYF4Synthesis of Yb/Nd core-shell type up-conversion nano material (UCNPs)
0.4mM core-shell precursor LnCl3Aqueous solution (comprising 0.04852g YCl)3·6H2O、0.07172g NdCl3·6H2O、0.01549g YbCl3·6H2O) was added to a three-necked flask and heated to 100 ℃ until solid chloride was formed. Then, OA 7.5mL and ODE 15mL were added to obtain mixture 2. The mixture 2 is heated to 150 ℃ and reacts for 1.5h,stirring to form a homogeneous solution, and then cooling to room temperature. Then, 4mL of pre-prepared Ca was added2+Doped NaYF4:Yb3+/Tm3+Solution and containing NaOH 0.04g and NH4F0.0592 g of 5mL of methanol solution are added dropwise to the reaction and stirred vigorously at 50 ℃ for 30 min. The solution was heated to 100 ℃ for 30min and cyclohexane and methanol were evaporated. The solution was then heated at 300 ℃ for 1.5h and then cooled to room temperature. All experiments were performed under argon. Finally, 2 volumes of absolute ethanol were added for precipitation, centrifuged at 12000rpm for 5min and washed several times with ethanol/cyclohexane (1:1 v/v). Finally, drying at 60 ℃ for 12h to obtain UCNPs.
Preparation of UCNPs-Cas9
A mixture of polyacrylic acid (PAA)0.5g and diethylene glycol 10mL was heated to 110 ℃ for 1 hour. 2mL of cyclohexane containing 30mg of UCNPs was added dropwise to the reaction, and stirred at 110 ℃ for 1 h. The solution was then heated to 240 ℃ for 1 hour and then cooled to room temperature. Dilute hydrochloric acid (pH4-5) was added, followed by vortexing and centrifugation at 12000rpm for 5 min. Carboxyl-functionalized UCNPs (UCNPs-PAA) are obtained.
Avidin was bound to the surface of UCNPs-PAA using 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide (EDC)/N-hydroxysuccinimide (NHS) covalent chemistry. The specific method comprises the following steps: 1mg of UNCPs-PAA, 50mg of EDC and 25mg of NHS were dispersed in 1mL of 2- (n-morpholine) glycolic acid buffer (MES, 0.1M, pH5.5) and incubated at 37 ℃ for 1h with gentle rotation. Then, 1mg of avidin was immediately added, and the pH was adjusted to 8. The reaction solution was kept incubated overnight at 4 ℃. The obtained UCNPs-Avidin was washed 3 times. 1mg of the obtained UCNPs-Avidin (calculated as Avidin) was resuspended in 600ul PBS, then mixed with 4mg of PC Biotin-NHS Ester (resuspended in 400ul PBS, purchased from sigma) solution, rotated for 2h at 37 ℃, and nanoparticles UNCPs-Avidin/PCB were collected and washed 3 times with PBS; simultaneously mixing NLS-Cas9-EGFP protein and sgRNA in PBS for 10min (37 ℃) to form CRISPR/Cas9 (or called Cas9 RNP, Cas 9/sgRNA); then the CRISPR/Cas9 and the obtained nanoparticle UNCPs-Avidin/PCB are rotated at 4 ℃ overnight for 12h to obtain UCNPs-Cas 9. The mixture was then dialyzed using an ultrafiltration spin column (vivaspin500,300kd) and unbound CRISPR/Cas9 was discarded. The recovered UCNPs-Cas9 was resuspended in500 ul PBS and stored briefly at 4 ℃.
The above products were subjected to spectral analysis and characterization of morphology, size, charge, etc. by uv-vis spectrophotometer, negative staining Electron Microscope, Transmission Electron Microscope (TEM), Scanning Electron Microscope (SEM), Dynamic Light Scattering (DLS), etc.
The experimental results are shown in fig. 2, 3, and 5D. The results show that: calcium doped NaYF4:Yb3+/Tm3+Particles with an average diameter of 41nm (FIGS. 2A-B, FIG. 3A). NaYF4:Yb/Tm/Ca@NaYF4Yb/Nd is a core-shell structure with an average diameter of 64nm (FIGS. 2C-D, FIG. 3B). HRTEM and SAED showed that the lattice fringe spacing of UCNPs was 0.52nm, corresponding to the typical (100) planes of hexagonal structures (fig. 2E-F). XRD showed that UCNPs have hexagonal phase because diffraction peaks can be well indexed to hexagonal beta-NaYF4(JCPDS card No.28-1192) (FIG. 3C). Transmission electron microscopy elemental analysis showed detailed UCNPs composite structures (fig. 3D). These results indicate that NaYF4:Yb/Tm/Ca@NaYF4Yb/Nd core-shell UCNPs have been successfully synthesized.
Uv-vis spectroscopy, FITR spectroscopy (fig. 3E-F) and zeta potential (fig. 5D) measurements demonstrate the surface modification of water-soluble carboxyl functionalized UCNPs-PAA. As shown in fig. 3E-F, the major uv absorbance maxima of avidin blue-shifted after UCNPs-PAA modification. FTIR at 1737cm-1And 1558cm-1The visible absorption peaks at (A) indicate tensile oscillations of the C ═ O and COO-groups, indicating effective modification of the carboxyl groups, and at 1643cm-1Bending vibrations of N-H were also observed at (amide). FIG. 5D shows that the zeta potential of UCNPs after PAA modification is about-46.46 mV; after coupling of avidin, the zeta potential is approximately 22.02 mV; these results indicate that the synthesis of UCNPs-Avidin was successful. The fluorescence intensity of UCNPs-PAA was not reduced compared to UCNPs. In addition, the ultraviolet-visible absorption light (UV-vis) absorption of the PCB partially overlaps with the emission spectrum of UCNPs (fig. 3G).
Example 3 preparation and characterization of biomimetic Nanoparticulate UCNPs-Cas9@ CM
1. Extraction of cell membrane fragments
HepG2.2.15 and HepAD38 cells were selected as hepatocyte models and cell membrane debris (CMs) were collected. The following procedures were carried out according to the cell membrane protein and cytoplasmic protein extraction kit (Biyuntian, product code P0033): first, cells were scraped from the culture dish using a cell scraper, collected in an EP tube, and the cell pellet was gently resuspended in an appropriate amount of ice-cooled PBS, counted, and then centrifuged at 600g for 5 minutes at 4 ℃ to pellet the cells. 1ml of membrane protein extraction reagent A with PMSF added before use is added into 5000 ten thousand cells, the cells are gently and fully suspended, and the mixture is placed in ice bath for 10-15 minutes. The cell suspension was transferred to a glass homogenizer pre-cooled in an ice bath and homogenized at about 30-50 deg.f. The supernatant was then carefully collected into a new EP tube by centrifugation at 700g for 10 minutes at 4 ℃. Finally, centrifugation was carried out at 14000g for 30 minutes at 4 ℃ to precipitate cell membrane debris. The supernatant was discarded, and the precipitate was freeze-dried and stored at-80 ℃. And the extracted cell membrane fragments were characterized, and the results are shown in fig. 4.
2. Preparation of UCNPs-Cas9@ CM
And (3) sequentially extruding the mixed solution of the UCNPs-Cas9 and the cell membrane fragments by using polycarbonate filter membranes with the pore diameters of 400nm and 200 nm. After repeated 21 cycles of squeezing, the cell membranes remaining in the supernatant were removed by centrifugation, and the obtained UCNPs-Cas9@ CM was replaced in PBS buffer and stored at 4 ℃.
The characterization of the cell membrane was performed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). First, protein electrophoresis was performed according to standard protocols. Then, staining with Coomassie brilliant blue, and destaining with glacial acetic acid overnight, protein bands were visible. For Western blot analysis, cell membrane proteins were electrophoretically blotted onto nitrocellulose membranes. Detection was performed using the indicated antibodies, including GAPDH (Proteintetech, #60004-1-Ig), Na +/K + -ATPase (Proteintetech, #14418-1-AP), histone H3(bimake, # A5737), cytochrome c (bimake, # A5184), pan-cadherin (bimake, # A5614), and secondary goat anti-rabbit IgG (Proteitech, # 000001-2). The purity of the cell membrane extraction was analyzed by observing the signal with ECL reagent (Millipore).
The release of Cas9 RNP was studied using an NIR laser (Catharan laser technology, Inc., China) at a wavelength of 808 nm. The UV absorption spectrum was measured with a Nano-500 spectrophotometer.
The results of the experiments are shown in FIGS. 4-6. From the results, it was found that the extracted cell membrane had no nucleus, mitochondria, and other organelles, indicating that the cell membrane had a high purity (FIG. 4A), and the particle size and zeta potential of the cell membrane were measured by Dynamic Light Scattering (DLS) (FIGS. 4B-C); transmission electron microscopy images show that UCNPs-Cas9@ CM has a core-shell structure with an outer shell thickness of about 10nm (FIG. 5A), while its surface morphology was examined by scanning electron microscopy (FIG. 5B); particle size and zeta potential were measured by Dynamic Light Scattering (DLS) (fig. 5C-D); figure 5E shows that the membrane proteins in the source cell membrane are widely retained and there are bands corresponding to monomeric avidin (17kDa) and Cas9(160kDa), indicating that avidin and Cas9 were successfully embedded in biomimetic nanopreparations; in 10ul of UCNPs-Cas9@ CM solution, the Cas9 protein band is about 1/3 of the pure Cas9 protein band (36 pmol); therefore, each 10ul of UCNPs-Cas9@ CM solution contains about 12pmol of Cas 9; FIG. 5F shows the results for pan cadherin and Na+/K+ATPase (membrane marker) retention, but not GAPDH (cytoplasmic marker), cytochrome C (mitochondrial marker) and histone H3 (nuclear marker), indicating selective retention of membrane proteins; therefore, cell membrane fragments are successfully coated on the UCNPs-Cas9 nanoparticles; from FIG. 5G, UCNPs-Cas9@ CM also showed good stability, with the hydrodynamic diameter change almost constant over 7 days; FIG. 5H shows that absorbance at 280nm increases with increasing NIR exposure time, whereas the NIR-unexposed group does not have this trend; CLSM in figure 6 shows that the position of GFP-tagged Cas9 is located in the cytoplasm after 3h of co-culture of cells with UCNPs-Cas9@ CM; at 6 hours under NIR irradiation, UCNPs-Cas9@ CM showed GFP fluorescence in the nucleus, whereas GFP fluorescence of the control group (without NIR) appeared only in the cytoplasm (fig. 5I); therefore, the nano-preparation of the invention has the potential of remotely controlling the time and space of CRISPR/Cas9 release.
Example 4 study of UCNPs-Cas9@ CM in vitro immune escape and isotype targeting
The anti-phagocytosis ability of UCNPs-Cas9@ CM on mouse macrophage RAW264.7 was studied by using UCNPs-Cas9 as a control. RAW264.7 (mouse macrophage) cells were seeded in 24-well culture plates, on which cell-climbing sheets were spread. Cells were co-incubated with GFP-labeled UCNPs-Cas9 and UCNPs-Cas9@ CM in DMEM medium. Cells were then fixed with 4% paraformaldehyde for 20min, mounted with DAPI-containing antifluorescent quenchers, and visualized by confocal laser scanning microscopy (CLSM, leica tcssp8, germany). In addition, the level of accumulation of Cas9-GFP in cells was analyzed using flow cytometry (beckmann coulter, usa). The results are shown in FIGS. 7A and 8.
From the results, it can be seen that: fluorescence shown in the cells showed that RAW264.7 cells internalized a large amount of UCNPs-Cas9 after co-culture for 6 h. In contrast, RAW264.7 cells co-cultured with UCNPs-Cas9@ CM exhibited very weak fluorescent signals. Furthermore, flow cytometry was used to assess its internalization efficiency, consistent with the results observed for CLSM. These results indicate that the cell membrane-coated particles are effective in inhibiting the uptake behavior of macrophages.
In order to verify the homotypic targeting capability of UCNPs-Cas9@ CM, the invention evaluates the UCNPs-Cas9 nano-carrier (named UCNPs-Cas9@ CM) coated by the HepG2.2.15 cell membrane in HepG2.2.15, 293T (human embryonic kidney cells) and HeLa (human cervical cancer cells)2.2.15) Was evaluated for cellular internalization. The results show that: UCNPs-Cas9@ CM2.2.15Preferentially accumulated in HepG2.2.15 cells and showed higher fluorescence intensity. In contrast, the fluorescence intensity of the heterotypic cell group was much weaker (FIG. 7B). The Mean Fluorescence Intensity (MFI) of each cell was then determined by flow cytometry. The data show that the MFI content in HepG2.2.15 cells was about 3.5-4.1 fold compared to other cells (FIG. 7B). Furthermore, the internalization rate of the cells was faster over time (fig. 9). These results indicate that UCNPs-Cas9@ CM has a high targeting specificity for the source cell.
Example 5 in vitro therapeutic Effect of UCNPs-Cas9@ CM
1. Cell viability assay
After 12 hours of culturing hepg2.2.15 and HepAD38 cells in 96-well plates, treatment was performed with different concentrations of UCNPs-Cas9@ CM, NIR power and irradiation time. PBS was the negative control.Then, 10% CCK-8 solution was added to each well and incubated for 4 h. By measuring OD450Values to assess cell viability.
1.1 the effect of different NIR power and irradiation time on cell viability was examined before UCNPs-Cas9@ CM treated cells. The results are shown in FIG. 10. From the results, it can be seen that: different NIR power (fixed irradiation time of 20 minutes) and different illumination time (fixed irradiation power of 2W/cm)2) Viability was not affected on hepg2.2.15 and HepAD38 cells (fig. 10A, 10B).
1.2 after the UCNPs-Cas9@ CM is added to treat the cells, the influence of different concentrations of UCNPs-Cas9@ CM (without NIR) on the cell viability is researched; different concentrations of UCNPs-Cas9@ CM at fixed laser power and illumination time (2W/CM)220min) on cell viability. The results are shown in FIG. 10. From the results, it can be seen that: under the above conditions, there was no significant effect on cell viability (fig. 10C, 10D).
1.3 the temperature change was observed by irradiating the UCNPs-Cas9@ CM solution. The temperature distribution results are shown in fig. 11. From the results, it can be seen that: in the experimental process, 1min irradiation is adopted and then the 2min interval is stopped, and UCNPs-Cas9@ CM can not cause damage to cells due to overhigh heat production.
In vitro Effect detection of UCNPs-Cas9@ CM
HepG2.2.15 and HepAD38 cells were cultured in 96-well plates for 12 hours, then further cultured with UCNPs-Cas9@ CM (Cas9 concentration 0.06uM) for 4 hours, and then irradiated with NIR at a power of 2W/CM2Irradiation time is 20 minutes, irradiation is 1 minute, interval is 2 minutes, and the cycle is repeated. PBS was the negative control.
2.1UCNPs-Cas9@ CM cleavage of HBV cccDNA efficiency assay
After further 3 days of culture, genomic DNA was isolated from HepAD38 cells and HepG2.2.15 cells, respectively, using the AllPureDNA/RNA kit (magenta, China). The sgRNA17 fragment acting on the target gene was amplified by PCR, and the DNA amplified by PCR was digested with T7EI and analyzed by agarose gel electrophoresis, the results of which are shown in FIG. 12A. Meanwhile, PCR amplification products of HepG2.2.15 cells were cloned into pTOPO-Blunt vector (Chinese Mei5, China) and sequenced, as shown in FIG. 12B, C.
From the results, UCNPs-Cas9@ CM can successfully cleave the gene HBV cccDNA (fig. 12A), with high cleavage efficiency; the PCR amplicons of the UCNPs-Cas9@ CM + NIR treatment group showed DNA sequencing doublet confirming that the HBV cccDNA site was mutated (fig. 12B-C).
Detection of HBV3.5kbRNA, HBVDNA and HBVcccDNA
The RT-qPCR method was used to detect HBV3.5kbRNA, intracellular HBV DNA and HBV cccDNA levels.
HBV DNA was isolated from HepG2.2.15 and HepAD38 cells. The specific method comprises the following steps: first, cells were lysed in 0.5ml core lysis buffer (10mM Tris-HCl pH8.0,1mM EDTA, 1% NP-40, 2% sucrose) at 37 ℃ for 15 minutes. After centrifugation, 4ul DNaseI (5IU/mL) and 5ul MgCl were used2(1M) treatment at 37 ℃ for 4 hours. Further centrifugation, 200ul of 35% PEG8000 and supernatant incubated in ice bath for 1 hour, precipitated HBV core capsids. Then treated with proteinase K at 45 ℃ for 12 h. HBV DNA was purified by phenol/chloroform (1:1) extraction, precipitated with ethanol, and resuspended in TE buffer. The extracted HBV DNA uses a pair of specific primers (HBV-F)2150And HBV-R2300) Quantification was performed by qPCR method.
HBVcccDNA is isolated by using a modified Hirt method. The specific method comprises the following steps: the cells were lysed in 0.5ml SDS lysis buffer (50mM Tris-HCl, pH8.0,10mM EDTA, 150mM sodium chloride, 1% SDS) at 37 ℃ for 15 minutes, and then the lysates were incubated with 125ul KCl (2.5M) overnight at 4 ℃. After centrifugation, the supernatant was extracted with phenol/chloroform (1:1), precipitated with isopropanol, washed with ethanol and resuspended in TE buffer. HBV cccDNA is detected by adopting taqman probe qRT-PCR.
Real-time fluorescent quantitative polymerase chain reaction (qRT-PCR) was used to detect expression of HBV pgRNA. The specific method comprises the following steps: cells were seeded overnight in 24-well plates and then treated with PBS and UCNPs-Cas9@ CM (Cas9 concentration of 0.06uM), respectively. After 3h incubation, an NIR laser (2W/cm) at 808nm was used2) Irradiation was carried out for 20min (1min after 2 min). After 72h, RNA was extracted from the cells using the AllPureDNA/RNA kit, followed by reverse transcription using the cDNA synthesis kit (Takara). The qRT-PCR was performed using SYBR Green qPCR Master Mix (Bimake, China) and ABI7500 real-time PCR system (applied biosystems, USA). Normalizing transcription of the target gene to GAPDH and using 2-ΔΔCTThe results were analyzed by the method. The sequences of the primers used are shown in Table 4, SEQ ID NO. 13-21.
TABLE 4 primer sequences
2.3 detection of HBsAg and HBeAg
The levels of HBsAg and HBeAg in the cell culture supernatants of HepG2.2.15 and HepAD38 were determined using an ELISA kit (Kowa Biotechnology, Shanghai, China).
The results are shown in FIGS. 12D-H. From the results, it is known that, compared with the negative control group, HBV3.5kbRNA, intracellular HBVDNA, HBVcccDNA and HBV virus antigen are all significantly reduced after the cells are incubated with UCNPs-Cas9@ CM. The UCNPs-Cas9@ CM can eliminate HBV cccDNA in cells and has obvious antiviral effect. The detection shows that the effect is obviously better than UCNPs-Cas9, and CMs has no treatment effect on resisting HBV.
Example 6 antiviral Effect of UCNPs-Cas9@ CM in vivo
HBV-Tg mice with higher HBVDNA, HBsAg level and HBeAg level were selected and randomly divided into two groups of 3 mice each. Mice were then injected 3 consecutive days with either PBS or UCNPs-Cas9@ CM at a concentration of 2mg/kg (Cas9 concentration) per UCNPs-Cas9@ CM injection, PBS groups were injected with equal volume solutions of UCNPs-Cas9@ CM, and then the liver was irradiated with NIR laser for 30min (1min, 2min off, cycle). On day 14 after injection, blood was collected from the eyeball of the mouse, then the mouse was sacrificed by dislocation of cervical vertebrae, and the liver and other major organs of the mouse were dissected.
Security assessment of UCNPs-Cas9@ CM
During treatment, body weight was monitored every 2 days after injection. To further analyze the excretion of UCNPs-Cas9@ CM in vivo, ICP-MS was used to determine the fecal and renal excretion of lanthanide ions (Y)3+) And (4) concentration. Respectively carrying out blood routine and blood biochemical detection on the blood of the mouse and carrying out tissue treatment on the main organs of the mouseChemical analysis to evaluate toxicity based on UCNPs-Cas9@ CM. The results of the experiment are shown in FIG. 13.
From the results, it can be seen that: after co-incubation with mouse blood cells with different concentrations of UCNPs-Cas9@ CM, no hemolysis was detected (fig. 13A). In addition, there was no significant change in blood analysis, both routine and biochemical (fig. 13B) and body weight (fig. 13C) in the mice in both groups. Y in urine and feces of mice3+The levels gradually decreased over time, suggesting that UCNPs could be efficiently excreted in vivo (fig. 13D). HE staining of the major organs of both groups of mice showed that no significant differences were found after treatment (fig. 13E). These results again demonstrate that UCNPs-Cas9@ CM has good biocompatibility.
In vivo antiviral action of UCNPs-Cas9@ CM
HBV DNA, HBsAg and HBeAg in the blood of the mouse and HBsAg and HBe in the liver cell are respectively detected to evaluate the in vivo antiviral effect of UCNPs-Cas9@ CM. The results of the experiment are shown in FIG. 14.
After UCNPs-Cas9@ CM and NIR light treatment, the secretion levels of HBV DNA, HBsAg and HBeAg in mouse serum can be obviously reduced to different degrees (figure 14A-C), and the HBsAg and HBe levels of mouse liver cells are also reduced through immunohistochemical detection (figure 14D). This is consistent with in vitro experimental results.
Example 7 detection of off-target Effect of UCNPs-Cas9@ CM
After HepG2.2.15 cells and mice were treated with UCNPs-Cas9@ CM, respectively, according to the methods of examples 5-2 and 6 above, genomic DNA was isolated from HepG2.2.15 cells and mouse liver tissues, respectively, using the AllPureDNA/RNA kit (magenta, China). Potential off-target sites of sgRNA17 were predicted by bioinformatics software, and off-target genomic sites were amplified using specific primers whose sequences are shown in Table 5(h: human, m: mouse), SEQ ID NO. 22-47. The product was tested for T7EI and the results are shown in FIG. 15. 15A, B is the in vitro off-target effect of UCNPs-Cas9@ CM: the light gray in A is the list of off-target sequences of mismatched sites and mismatched bases; b, detecting by adopting T7EI, and carrying out agarose gel electrophoresis on the obtained product to determine potential off-target effects in different target sequences (Chr #) of the chromosome; 15C, D is the in vivo off-target effect of UCNPs-Cas9@ CM: light gray in C is the list of off-target sequences of mismatched sites and mismatched bases; d is detection by T7EI, and agarose gel electrophoresis is carried out on the obtained product to determine potential off-target effect in different target sequences (Chr #) of chromosomes.
TABLE 5 specific primers
The above results indicate that the off-target effect of UCNPs-Cas9@ CM is negligible. sgRNA17 can specifically recognize and proficiently edit HBV.
Finally, it is noted that the above embodiments are only used for illustrating the technical solutions of the present invention/utility model and not for limiting, and although the present invention/utility model has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made to the technical solutions of the present invention/utility model without departing from the spirit and scope of the technical solutions of the present invention/utility model, which should be covered in the scope of the claims of the present invention/utility model.
SEQUENCE LISTING
<110> Min Hospital in Rongchang district of Chongqing City
<120> near-infrared response bionic nano preparation and preparation method and application thereof
<130> CQ202110235
<160> 47
<170> PatentIn version 3.5
<210> 1
<211> 19
<212> DNA
<213> Artificial sequence
<400> 1
ttcagttata tggatgatg 19
<210> 2
<211> 20
<212> DNA
<213> Artificial sequence
<400> 2
<210> 3
<211> 20
<212> DNA
<213> Artificial sequence
<400> 3
<210> 4
<211> 124
<212> DNA
<213> Artificial sequence
<400> 4
aagctaatac gactcactat aggttcagtt atatggatga tggttttaga gctagaaata 60
gcaagttaaa ataaggctag tccgttatca acttgaaaaa gtggcaccga gtcggtgctt 120
tttt 124
<210> 5
<211> 125
<212> DNA
<213> Artificial sequence
<400> 5
aagctaatac gactcactat aggaatgtca acgaccgacc ttggttttag agctagaaat 60
agcaagttaa aataaggcta gtccgttatc aacttgaaaa agtggcaccg agtcggtgct 120
ttttt 125
<210> 6
<211> 125
<212> DNA
<213> Artificial sequence
<400> 6
aagctaatac gactcactat aggcttcacc tctgcacgtc gcagttttag agctagaaat 60
agcaagttaa aataaggcta gtccgttatc aacttgaaaa agtggcaccg agtcggtgct 120
ttttt 125
<210> 7
<211> 20
<212> DNA
<213> Artificial sequence
<400> 7
<210> 8
<211> 20
<212> DNA
<213> Artificial sequence
<400> 8
<210> 9
<211> 18
<212> DNA
<213> Artificial sequence
<400> 9
ctctctttac gcggactc 18
<210> 10
<211> 19
<212> DNA
<213> Artificial sequence
<400> 10
gcgcagacca atttatgcc 19
<210> 11
<211> 20
<212> DNA
<213> Artificial sequence
<400> 11
<210> 12
<211> 20
<212> DNA
<213> Artificial sequence
<400> 12
<210> 13
<211> 22
<212> DNA
<213> Artificial sequence
<400> 13
aaggtcggag tcaacggatt tg 22
<210> 14
<211> 23
<212> DNA
<213> Artificial sequence
<400> 14
ccatgggtgg aatcatattg gaa 23
<210> 15
<211> 20
<212> DNA
<213> Artificial sequence
<400> 15
<210> 16
<211> 20
<212> DNA
<213> Artificial sequence
<400> 16
gagggagttc ttcttctagg 20
<210> 17
<211> 22
<212> DNA
<213> Artificial sequence
<400> 17
cctagtagtc agttatgtca ac 22
<210> 18
<211> 22
<212> DNA
<213> Artificial sequence
<400> 18
tctataagct ggaggagtgc ga 22
<210> 19
<211> 19
<212> DNA
<213> Artificial sequence
<400> 19
ctccccgtct gtgccttct 19
<210> 20
<211> 18
<212> DNA
<213> Artificial sequence
<400> 20
<210> 21
<211> 28
<212> DNA
<213> Artificial sequence
<400> 21
acgtcgcatg gagaccaccg tgaacgcc 28
<210> 22
<211> 20
<212> DNA
<213> Artificial sequence
<400> 22
gcatgtgatc agccatgtat 20
<210> 23
<211> 20
<212> DNA
<213> Artificial sequence
<400> 23
<210> 24
<211> 20
<212> DNA
<213> Artificial sequence
<400> 24
gtgtttcctc gaggtccagg 20
<210> 25
<211> 20
<212> DNA
<213> Artificial sequence
<400> 25
<210> 26
<211> 20
<212> DNA
<213> Artificial sequence
<400> 26
<210> 27
<211> 20
<212> DNA
<213> Artificial sequence
<400> 27
<210> 28
<211> 20
<212> DNA
<213> Artificial sequence
<400> 28
<210> 29
<211> 20
<212> DNA
<213> Artificial sequence
<400> 29
<210> 30
<211> 20
<212> DNA
<213> Artificial sequence
<400> 30
<210> 31
<211> 20
<212> DNA
<213> Artificial sequence
<400> 31
<210> 32
<211> 20
<212> DNA
<213> Artificial sequence
<400> 32
<210> 33
<211> 20
<212> DNA
<213> Artificial sequence
<400> 33
<210> 34
<211> 22
<212> DNA
<213> Artificial sequence
<400> 34
tccccaacta aatcatcaac ct 22
<210> 35
<211> 20
<212> DNA
<213> Artificial sequence
<400> 35
<210> 36
<211> 20
<212> DNA
<213> Artificial sequence
<400> 36
<210> 37
<211> 20
<212> DNA
<213> Artificial sequence
<400> 37
<210> 38
<211> 21
<212> DNA
<213> Artificial sequence
<400> 38
agctagatct gaaggacggg a 21
<210> 39
<211> 20
<212> DNA
<213> Artificial sequence
<400> 39
<210> 40
<211> 20
<212> DNA
<213> Artificial sequence
<400> 40
<210> 41
<211> 20
<212> DNA
<213> Artificial sequence
<400> 41
<210> 42
<211> 20
<212> DNA
<213> Artificial sequence
<400> 42
<210> 43
<211> 20
<212> DNA
<213> Artificial sequence
<400> 43
<210> 44
<211> 20
<212> DNA
<213> Artificial sequence
<400> 44
<210> 45
<211> 20
<212> DNA
<213> Artificial sequence
<400> 45
gaggcccctt gaacagactc 20
<210> 46
<211> 20
<212> DNA
<213> Artificial sequence
<400> 46
<210> 47
<211> 21
<212> DNA
<213> Artificial sequence
<400> 47
caccctgggg aacaagttag t 21
Claims (10)
1. A near-infrared response bionic nano preparation is characterized in that: the cell membrane comprises a hepatocyte model cell membrane and a nano-carrier wrapped in the cell membrane, wherein the nano-carrier comprises near-infrared response up-conversion nanoparticles and CRISPR/Cas9, avidin proteins are modified on the surfaces of the up-conversion nanoparticles, and biotin-modified photolysis molecules are connected between the avidin proteins and CRISPR/Cas 9.
2. The near-infrared responsive biomimetic nano-formulation of claim 1, wherein: the hepatocyte model is one of an HBV replication hepatocyte model, an HBV infection hepatocyte model and a primary hepatocyte model.
3. The near-infrared responsive biomimetic nano-formulation of claim 1, wherein: the near-infrared response up-conversion nano particles are of a core-shell structure, Ca2+Doped NaYF4:Yb3+/Tm3+As a nucleus, NaYF4Yb/Nd is the shell.
4. The near-infrared responsive biomimetic nano-formulation of claim 1, wherein: the biotin-modified photolytic molecule is PC biotin-nhs ester.
5. The near-infrared responsive biomimetic nano-formulation of claim 1, wherein: the CRISPR/Cas9 comprises a Cas9 protein and sgRNAs, and DNA sequences corresponding to the sgRNAs are shown in SEQ ID NO. 1-3.
6. A preparation method of a near-infrared response bionic nano preparation is characterized by comprising the following steps: the method comprises the following steps:
1) construction of CRISPR/Cas 9: designing and synthesizing sgRNA, and co-incubating the sgRNA and Cas9 protein to prepare CRISPR/Cas 9;
2) preparing a nano-carrier UCNPs-Cas 9: synthesizing up-conversion nanoparticles, carrying out hydrophilic modification and Avidin surface modification on the up-conversion nanoparticles to obtain UNCPs-Avidin, then carrying out a connection reaction with a biotin-modified photolysis molecule to form nanoparticle UNCPs-Avidin/PCB, and co-incubating the nanoparticle UNCPs-Avidin/PCB with the CRISPR/Cas9 prepared in the step 1) to obtain a nano-carrier UCNPs-Cas 9;
3) preparing a bionic nano preparation UCNPs-Cas9@ CM: extracting HBV cell membranes of a liver cancer cell replication model, mixing the cell membranes with UCNPs-Cas9 prepared in the step 2), and repeatedly extruding through a polycarbonate filter membrane to obtain UCNPs-Cas9@ CM.
7. The method for preparing a near-infrared response biomimetic nano-formulation according to claim 6, characterized in that: in the step 1), the molar mass ratio of the sgRNA to the Cas9 protein is 1:1-10:1, the co-incubation time is 5-15min, and the temperature is 37 ℃.
8. The method for preparing a near-infrared response biomimetic nano-formulation according to claim 6, characterized in that: in step 2), the surface of the up-conversion nanoparticle comprises an oleic acid ligand, the modifier used in the hydrophilic modification is polyacrylic acid, and the method for surface modification of avidin comprises the following steps: linking avidin on the surface of the upconversion nanoparticle by using EDC/NHS; the temperature of the connection reaction is 37 ℃ and the time is 2 h; the mass ratio of Avidin to biotin-modified photolytic molecules in UNCPs-Avidin is 1: 4; the temperature of the co-incubation is 4 ℃ and the time is 8-12 h.
9. The method for preparing a near-infrared response biomimetic nano-formulation according to claim 6, characterized in that: in the step 3), the aperture of the polycarbonate filter membrane is 200nm or 400 nm.
10. Use of a near-infrared responsive biomimetic nano-formulation according to any of claims 1-5 in the preparation of a medicament for the treatment of hepatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111160742.7A CN113876736B (en) | 2021-09-30 | 2021-09-30 | Near-infrared response bionic nano preparation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111160742.7A CN113876736B (en) | 2021-09-30 | 2021-09-30 | Near-infrared response bionic nano preparation and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113876736A true CN113876736A (en) | 2022-01-04 |
| CN113876736B CN113876736B (en) | 2022-11-29 |
Family
ID=79004825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111160742.7A Active CN113876736B (en) | 2021-09-30 | 2021-09-30 | Near-infrared response bionic nano preparation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113876736B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110628767A (en) * | 2019-07-26 | 2019-12-31 | 华中农业大学 | Biomineralized CRISPR/Cas9RNPs nanoparticles, preparation method and application thereof in gene editing |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109971790A (en) * | 2019-04-01 | 2019-07-05 | 南京大学 | A kind of near infrared light controlling gene edit methods |
| CN111041049A (en) * | 2019-12-04 | 2020-04-21 | 江苏大学 | Preparation method and application of CRISPR-Cas13a system based on near-infrared light control |
| US20210222164A1 (en) * | 2016-06-29 | 2021-07-22 | The Broad Institute, Inc. | Crispr-cas systems having destabilization domain |
-
2021
- 2021-09-30 CN CN202111160742.7A patent/CN113876736B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210222164A1 (en) * | 2016-06-29 | 2021-07-22 | The Broad Institute, Inc. | Crispr-cas systems having destabilization domain |
| CN109971790A (en) * | 2019-04-01 | 2019-07-05 | 南京大学 | A kind of near infrared light controlling gene edit methods |
| CN111041049A (en) * | 2019-12-04 | 2020-04-21 | 江苏大学 | Preparation method and application of CRISPR-Cas13a system based on near-infrared light control |
Non-Patent Citations (3)
| Title |
|---|
| YONGCHUN PAN等: "Near-infrared upconversion–activated CRISPR-Cas9 system: A remote-controlled gene editing platform", 《SCI. ADV.》 * |
| YUNXIA WU等: "Light-responsive charge-reversal nanovector for high-efficiency in vivo CRISPR/Cas9 gene editing with controllable location and time", 《NANO RESEARCH》 * |
| 贾玉涛等: "Li+增强Ho3+/Yb3+：Y2O3 纳米晶的上转化发光研究", 《红外与激光工程》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110628767A (en) * | 2019-07-26 | 2019-12-31 | 华中农业大学 | Biomineralized CRISPR/Cas9RNPs nanoparticles, preparation method and application thereof in gene editing |
| CN110628767B (en) * | 2019-07-26 | 2023-07-07 | 华中农业大学 | Biomineralization CRISPR/Cas9RNPs nano-particles, preparation method and application thereof in gene editing |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113876736B (en) | 2022-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bai et al. | Engineered targeting tLyp-1 exosomes as gene therapy vectors for efficient delivery of siRNA into lung cancer cells | |
| US7332586B2 (en) | Nanoparticle delivery vehicle | |
| Bruckman et al. | Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents | |
| CN109355310B (en) | ROS (reactive oxygen species) -responsive gene delivery vector as well as preparation method and application thereof | |
| Chu et al. | Biocompatible polyethylenimine-graft-dextran catiomer for highly efficient gene delivery assisted by a nuclear targeting ligand | |
| Li et al. | A siRNA-induced peptide co-assembly system as a peptide-based siRNA nanocarrier for cancer therapy | |
| US11904057B2 (en) | Nanoparticle-hydrogel composite for nucleic acid molecule delivery | |
| Qian et al. | Synthesis and preliminary cellular evaluation of phosphonium chitosan derivatives as novel non-viral vector | |
| EP3107549A1 (en) | Anionic polyplexes for use in the delivery of nucleic acids | |
| CN113876736B (en) | Near-infrared response bionic nano preparation and preparation method and application thereof | |
| CN108250267A (en) | A kind of polypeptide, the common assembly of polypeptide-siRNA inductions and application thereof | |
| Huang et al. | Genetic recombination of poly (l-lysine) functionalized apoferritin nanocages that resemble viral capsid nanometer-sized platforms for gene therapy | |
| Wang et al. | Theranostic magnetic nanoparticles for efficient capture and in situ chemotherapy of circulating tumor cells | |
| CN112972703A (en) | Gene editing nanocapsule and preparation method and application thereof | |
| WO2015121924A1 (en) | COMPOSITION FOR mRNA DELIVERY | |
| CN108148874B (en) | Application of degradable two-dimensional black phosphorus as gene editing vector | |
| Zhang et al. | A zwitterionic polymer-inspired material mediated efficient CRISPR-Cas9 gene editing | |
| Huang et al. | Gene delivery into brain capillary endothelial cells using Antp-modified DNA-loaded nanoparticles | |
| CN103320471A (en) | Non-viral gene vector and preparation method thereof | |
| JP6967810B2 (en) | Pharmaceutical composition for the prevention or treatment of liver cancer | |
| CN113265050A (en) | Degradable high polymer material, self-assembled nano composite and application | |
| BR102016017712A2 (en) | CARBON NANOParticles, FUNCTIONALIZED FOR NUCLEIC ACID DELIVERY, PREPARATION PROCESS AND USE | |
| Liang et al. | Efficient nanoparticle mediated gene silencing in human colon cancer cells | |
| CN116350803B (en) | mRNA drug delivery system taking papillomavirus-like particles as carrier and preparation method thereof | |
| CN114504657A (en) | Biomineralization nanometer material for treating duchenne muscular dystrophy and gene editing system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |